Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech

Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From

       - Phase I clinical testing of oral GDC-0917 recently completed -

- Company also provides bioavailability update on CUDC-101; announces progress
                        with CUDC-907 and Debio 0932 -

                  - Conference call today at 8:30 a.m. EST -

LEXINGTON, Mass., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS),
a drug development company seeking to develop next generation targeted small
molecule drug candidates for cancer treatment, today announced that it has
licensed from Genentech, a member of the Roche Group, (SIX: RO, ROG; OTCQX:
RHHBY), exclusive, worldwide rights for the development and commercialization
of GDC-0917, a small molecule that is designed to promote cancer cell death by
antagonizing inhibitor of apoptosis (IAP) proteins.

"We are very pleased to have entered into this agreement for GDC-0917, which
adds depth to our current pipeline of proprietary targeted anti-cancer agents
and further solidifies our relationship with our partner Genentech," said Dan
Passeri, Curis' President and Chief Executive Officer. "Importantly, we
anticipate that the $30 million non-dilutive royalty financing transaction
that we also announced this morning will provide us with sufficient capital to
progress GDC-0917 and our other programs to important development milestones."

"We value the relationship that we have with Curis, and Genentech is pleased
to enter into this agreement," said James Sabry, M.D., Ph.D., Vice President,
Genentech Partnering. "We have been impressed with the results of our recently
completed Phase I clinical trial and look forward to Curis' further
development of GDC-0917."

Genentech has recently completed a Phase I clinical trial of GDC-0917, in
which 42 people received daily oral doses of GDC-0917 for two weeks, followed
by a one week rest period. This 21-day cycle is repeated until disease
progression or study discontinuation for any other reason.The primary
endpoints of the study include evaluating the safety and tolerability and the
pharmacokinetics of GDC-0917 in people with solid tumors or lymphoma and
determining the maximum-tolerated-dose and a potential recommended dose for
further clinical studies.Secondary endpoints include a preliminary assessment
of anti-tumor activity of GDC-0917 and evaluating pharmacodynamic markers.
Genentech plans to present full study results at a medical conference in
mid-2013.Please refer to for additional study details.

"The results of the Phase I study with GDC-0917 have been encouraging,"
commented one of the principal investigators in Genentech's Phase I clinical
study, Dr. Anthony Tolcher, M.D., FRCP (C), Director of Clinical Research at
South Texas Accelerated Research Therapeutics (START) in San Antonio, Texas.
"We believe that IAP inhibition could prove to be an important approach in
cancer therapy and we look forward to working with Curis in upcoming clinical
studies of this exciting molecule," said Dr. Tolcher.

Curis has designated GDC-0917 as CUDC-427 and plans to continue the further
clinical development of CUDC-427, both as a single agent as well as in a Phase
I clinical trial in combination therapy, which if successful would enable
Curis to advance to Phase II combination clinical studies.

Under the terms of the license agreement, Curis will have the sole right and
responsibility for all research, development, manufacturing and
commercialization activities related to CUDC-427.Curis will pay Genentech
$9.5 million for an up-front license payment and technology transfer costs. In
addition, Genentech is entitled to receive milestone payments upon the first
commercial sale of CUDC-427 in certain territories and royalties on net sales
of CUDC-427.

In addition, Curis separately announced that, subject to the occurrence of
certain closing conditions, it will enter into a $30 million debt transaction
secured with certain future Erivedge™ royalties, with an investment fund
managed by Pharmakon Advisors.Upon closing, this capital will provide Curis
with an important source of funding for the further development of Curis'
proprietary programs, including CUDC-427.

About Inhibitor of Apoptosis Proteins

Impairment of programmed cell death or apoptosis often contributes to the
formation and progression of cancer, and evasion of apoptosis is one of the
primary strategies by which cancer cells develop resistance to anticancer
therapies. Inhibitor of apoptosis (IAP) proteins are a family of functionally
and structurally related proteins which include X-linked IAP (XIAP), cellular
IAPs (cIAP1 and cIAP2), and melanoma IAP (ML-IAP). They confer protection from
death-inducing stimuli by exerting a range of biological activities that
promote cancer cell survival and proliferation. Some even directly inhibit
caspases, critical players in the execution of apoptosis.

Mutations, amplifications and chromosomal translocations of IAP genes are
associated with various solid and hematologic cancer types, and increased IAP
expression has been associated with an unfavorable prognosis and poor outcome
for patients.

As a consequence, IAP proteins are considered promising molecular targets for
anticancer therapy.

About CUDC-427 (GDC-0917)

CUDC-427 is an orally bioavailable small molecule that triggers tumor cell
apoptosis by selectively antagonizing IAP proteins. CUDC-427 was designed to
mimic the endogenous IAP antagonist mitochondrial protein second
mitochondria-derived activator of caspases/direct IAP-binding protein
(Smac/DIABLO) that is released into the cytoplasm in response to pro-apoptotic

CUDC-427 has demonstrated single-agent and combination anti-tumor activity in
mouse xenograft tumor models when administered orally on a daily schedule, and
IND-enabling safety studies have shown it to be well tolerated when dosed
daily by oral administration, potentially enabling sustained target

In October 2010, an open-labeled, uncontrolled, dose-escalation, Phase I
clinical trial of CUDC-427 (NCT01226277; IAM4914g) began in patients with
refractory solid tumors or lymphoma. The study was designed to assess safety,
tolerability and pharmacokinetics of daily, oral doses of CUDC-427. Data from
this study are expected to be presented at an oncology conference in mid-2013.

Clinical Status Update on CUDC-101, CUDC-907 and Debio 0932

Curis also today provided a bioavailability update on CUDC-101, a
first-in-class small molecule drug candidate that has been designed as an
inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor
(EGFR) and epidermal growth factor receptor 2 (Her2). CUDC-101 is being
studied in a Phase I clinical study with an oral formulation in patients with
advanced solid tumors as well as in a separate Phase I clinical study with an
intravenous (IV) formulation in patients with locally advanced head and neck
cancer.Curis has determined that the bioavailability observed in the first
cohort of patients from the Phase I clinical study of the oral formulation of
CUDC-101 were too low to warrant the enrollment of additional patients in the
current study.The Company is evaluating various options for the further
exploration of the oral formulation of CUDC-101, including those that may
increase the bioavailability of CUDC-101, pursuing alternative oral
formulations or routes of administration, as well as backup molecules whose
chemical properties may be more amenable to oral administration.

"We continue to believe that the compiled data of CUDC-101 support the
approach of targeting multiple nodes in cancer networks and consequently we
continue to evaluate alternatives for pursuing further development of
CUDC-101," stated Dan Passeri, Curis' President and Chief Executive Officer.

Curis also today announced that the FDA has provided its permission to proceed
to Phase I testing of CUDC-907, a first-in-class PI3K and HDAC inhibitor,
following its investigational new drug (IND) filing last month.Curis expects
to initiate this study in late 2012 or early 2013.

Finally, Curis also announced today that its licensee Debiopharm continues to
expand its development of Hsp90 inhibitor Debio 0932.In addition to its
ongoing Phase Ib study in solid tumor cancers and its ongoing Phase I/II
clinical trial in advanced non-small cell lung cancer (NSCLC), Debiopharm has
determined that it plans to initiate a separate Phase I/II clinical trial with
Debio 0932 in combination with Everolimus in renal cell carcinoma patients in
the second half of 2013.Curis is eligible to receive a milestone payment from
Debiopharm upon the treatment of the 5th patient of the Phase II portion of
this study.

Conference Call Information

Daniel Passeri, President and Chief Executive Officer of Curis, will host a
conference call today, November 28, 2012, at 8:30 a.m. EST, to review the
license agreement, financing transaction, CUDC-101, CUDC-907 and Debio 0932
updates and corporate strategy.

To access the live conference call, please dial (877) 868-1829 from the U.S.
or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The
conference ID number is 73717844. The conference call can also be accessed on
the Curis website at in the Investors section. A replay will be
available approximately two hours after the completion of the call through
12:00 p.m. EST, Saturday, December 1, 2012. To access the replay, please dial
(855) 859-2056 from the United States or (404) 537-3406 from other locations
and reference conference ID number 73717844.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its
innovative signaling pathway drug technologies to seek to create new targeted
small molecule drug candidates for cancer. Curis is building upon its previous
experiences in targeting signaling pathways, including in the Hedgehog
pathway, in its effort to develop proprietary targeted cancer programs. For
more information, visit Curis' website at

The Curis, Inc. logo is available at

Curis Cautionary Statement: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995, including without limitation statements regarding Curis' expectations
regarding the potential benefits of CUDC-427 and the importance of IAP as a
target for developing cancer therapies; Curis' expectation that the proceeds
of its royalty financing transaction will be sufficient to progress CUDC-427
and its other proprietary programs to importantmilestones;Curis' plans for
further clinical testing of CUDC-427 and Curis' plans with regard to the
further evaluation of CUDC-101 and for advancing CUDC-907 into Phase I
clinical testing.Forward-looking statements used in this press release may
contain the words "believes", "expects", "anticipates", "plans", "seeks",
"estimates", "assumes", "will", "may," "could" or similar expressions. These
forward-looking statements are not guarantees of future performance and
involve risks, uncertainties, assumptions and other important factors that may
cause actual results to be materially different from those indicated by such
forward-looking statements. For example, Curis may not be able to successfully
advance CUDC-427 into planned clinical studies or may otherwise experience
delays, setbacks and failures in its clinical development of CUDC-427
including the potential for CUDC-427 to cause unexpected toxicities and/or
fail to demonstrate sufficient safety and efficacy. Preclinical testing and
clinical studies of Curis' other programs in development, including CUDC-101
and CUDC-907, may be unsuccessful and may never achieve the requisite
regulatory approval needed for commercialization.Curis will require
substantial additional capital to fund the research and development of
CUDC-427 and its other programs, and the proceeds of its royalty financing
transaction may not be sufficient to fund its near-term capital requirements
for advancing these programs.Curis may not obtain or maintain necessary
patent protection for its programs and could become involved in expensive and
time consuming patent litigation and interference proceedings.Curis faces
substantial competition from other companies developing cancer
therapeutics.Unstable market and economic conditions may adversely affect
Curis' financial conditions and its ability to access capital to fund the
growth of its business. Curis also faces other important risks relating to its
business, operations, financial condition and future prospects that are
discussed in its Quarterly Report on Form 10-Q for the quarter ended September
30, 2012 and other filings that it periodically makes with the Securities and
Exchange Commission.

In addition, any forward-looking statements represent the views of Curis only
as of today and should not be relied upon as representing Curis' views as of
any subsequent date. Curis disclaims any intention or obligation to update any
of the forward-looking statements after the date of this press release whether
as a result of new information, future events or otherwise.

CONTACT: For More Information:
         Michael P. Gray
         Chief Financial and Chief Operating Officer
         Curis, Inc.

Curis, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.